arrow
M

Michael Millward

university of western australia and linear clinical research
H指数:61
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma

Grant, M.; Cipriani, B.; Corbin, A.; Miller, D.; Naylor, A.; Hughes, S.; McCarthy, T.; Ambarkhane, S.; Memon, D.; Millward, M.; 等. 低pH,高风险:一项探讨GPR65通路作为肾细胞癌新型治疗策略的叙事性综述。Cancers 2025, 17, 3883. [Google Scholar] [CrossRef] [PubMed]

Cancers
IF4.4
2026-03-040
OAAI
Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883

更正:Grant等人,《低pH,高风险:探索酸感受GPR65通路作为肾细胞癌新方法的叙事综述》。《Cancers》2025年第17卷,第3883页。

Cancers
IF4.4
2026-02-270
OAAI
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

YAP/TEAD抑制剂VT3989在实体瘤中的研究:一项1/2期临床试验

2025-10-190
PRE
Nivolumab for Resected Stage III or IV Melanoma at 9 Years

纳武利尤单抗治疗已切除III期或IV期黑色素瘤9年结果

2025-10-015
PRE
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
2024-09-091
OAAI
Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12

vemurafenib(VEM)和cobimetinib(COB)在BRAF V600突变实体瘤和一线(1L)非小细胞肺癌(NSCLC)中的II期试验:澳大利亚分子筛查和治疗(MoST)子研究12

2024-09-010
PRE
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes
2024-04-262
OA
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
2023-12-010
PRE